| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,603,934 | 3 | 60 |
Sells | $674,847 | 2 | 40 |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 3 | $1.6M | 0 | $0 | $1.6M |
| ORBIMED ADVISORS LLC | 10 percent owner | 0 | $0 | 2 | $674,847 | $-674,847 |
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic …
Over the last 12 months, insiders at Adicet Bio, Inc. have bought $1.6M and sold $674,847 worth of Adicet Bio, Inc. stock.
On average, over the past 5 years, insiders at Adicet Bio, Inc. have bought $7.86M and sold $1.45M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. (10 percent owner) — $1.6M.
The last purchase of 74,751 shares for transaction amount of $543,440 was made by RA CAPITAL MANAGEMENT, L.P. (10 percent owner) on 2026‑02‑20.
| 2026-04-08 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 72,939 0.7583% | $6.42 | $468,082 | +25.19% | |
| 2026-04-07 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 31,719 0.335% | $6.52 | $206,765 | +27.53% | |
| 2026-02-20 | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 74,751 0.7946% | $7.27 | $543,440 | +12.75% | ||
| 2026-02-19 | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 74,268 0.7918% | $7.21 | $535,472 | +7.73% | ||
| 2026-02-18 | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 74,577 0.7764% | $7.04 | $525,022 | +13.03% | ||
| 2025-10-08 | ORBIMED ADVISORS LLC | 10 percent owner | 5M 6.4668% | $1.00 | $5M | -44.41% | ||
| 2024-06-05 | Sale | Kauffman Michael | director | 5,900 0.0071% | $1.43 | $8,437 | -29.86% | |
| 2024-01-25 | ORBIMED ADVISORS LLC | 3.13M 7.0488% | $2.40 | $7.5M | -41.70% | |||
| 2024-01-25 | GORDON CARL L | 3.13M 7.0488% | $2.40 | $7.5M | -41.70% | |||
| 2023-10-02 | Schor Chen | President & CEO | 5,500 0.013% | $1.33 | $7,340 | +13.74% | ||
| 2023-09-29 | Sale | Schor Chen | President & CEO | 5,500 0.0127% | $1.36 | $7,481 | +9.12% | |
| 2023-09-28 | Sale | Schor Chen | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +4.93% | |
| 2023-09-28 | Schor Chen | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +4.93% | ||
| 2023-06-30 | DUBIN STEVE | director | 5,000 0.0115% | $2.40 | $12,000 | -27.78% | ||
| 2023-06-27 | ORBIMED ADVISORS LLC | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | |||
| 2023-06-27 | GORDON CARL L | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | |||
| 2023-02-15 | Sale | Healey Don | Chief Technology Officer | 4,533 0.0101% | $7.57 | $34,327 | -68.06% | |
| 2023-02-10 | Sale | Healey Don | Chief Technology Officer | 10,467 0.0247% | $7.98 | $83,476 | -68.37% | |
| 2022-11-10 | Sale | Schor Chen | President & CEO | 39,955 0.095% | $20.30 | $811,242 | -72.57% | |
| 2022-11-10 | Sale | Aftab Blake | Chief Scientific Officer | 6,967 0.0171% | $21.00 | $146,307 | -72.57% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 1182624 12.6329% | $3.75M | 3 | 0 | |
| ORBIMED ADVISORS LLC | 10 percent owner | 0 0% | $0 | 4 | 2 | <0.0001% |
| GORDON CARL L | 7526359 80.397% | $23.86M | 2 | 0 | <0.0001% | |
| SILVERSTEIN JONATHAN | 4830387 51.5985% | $15.31M | 1 | 0 | ||
| PureTech Health LLC | 10 percent owner | 2119696 22.6427% | $6.72M | 1 | 6 | |
| Sinclair Andrew | director | 2115385 22.5967% | $6.71M | 1 | 0 | <0.0001% |
| Schor Chen | President & CEO | 43469 0.4643% | $137,796.73 | 5 | 18 | +9.34% |
| DUBIN STEVE | director | 10900 0.1164% | $34,553.00 | 1 | 0 | <0.0001% |
$2,542,362 | 111 | 11.81% | $36.83M | |
$156,891,025 | 80 | -24.91% | $36.3M | |
$84,911,583 | 59 | 17.82% | $37.44M | |
$693,326 | 47 | -16.24% | $40.24M | |
$6,204,522 | 45 | 1.91% | $36.5M |
| Increased Positions | 36 | +59.02% | 4M | +123.13% |
| Decreased Positions | 28 | -45.9% | 637,127 | -18.92% |
| New Positions | 15 | New | 3M | New |
| Sold Out Positions | 19 | Sold Out | 122,964 | Sold Out |
| Total Postitions | 69 | +13.11% | 7M | +104.2% |
| Orbimed Advisors Llc | $6,310.00 | 7.15% | 715,446 | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $4,533.00 | 5.14% | 513,976 | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $4,157.00 | 4.71% | 471,313 | 0 | 0% | 2025-09-30 |
| Goldman Sachs Group Inc | $2,068.00 | 2.35% | 234,476 | -30 | -0.01% | 2025-09-30 |
| Vanguard Group Inc | $1,804.00 | 2.05% | 204,533 | 0 | 0% | 2025-09-30 |
| Carlyle Group Inc. | $1,625.00 | 1.84% | 184,295 | 0 | 0% | 2025-09-30 |
| Aquilo Capital Management, Llc | $1,354.00 | 1.54% | 153,512 | -4,688 | -2.96% | 2025-03-31 |
| Acadian Asset Management Llc | $1,249.00 | 1.42% | 141,593 | +11,930 | +9.2% | 2025-09-30 |
| Renaissance Technologies Llc | $1,008.00 | 1.14% | 114,309 | +42,195 | +58.51% | 2025-09-30 |
| Regeneron Pharmaceuticals, Inc. | $534.00 | 0.61% | 60,511 | 0 | 0% | 2025-09-30 |